clinical trial · NCT02809105
A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
Chronic ConstipationlinaclotidePlacebo
brief summary
The objective of this study is to verify the efficacy and investigate the safety of the study drug when ASP0456 is administered orally for 4 weeks and 52 weeks.
started
Jun 24, 2016
primary completion
Nov 14, 2016
completion
Nov 10, 2017
last updated
Oct 18, 2024
detailed description
This study consists of two parts. In Part I, ASP0456 or placebo will be administered orally in a blind manner. In Part II, the long-term safety and efficacy of ASP0456 will be evaluated in patients who have participated in the study and completed the Part I.
official title
Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol